Published in J Clin Pharmacol on July 01, 2001
Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects. Eur J Clin Pharmacol (2005) 0.88
The effect of CYP2J2, CYP3A4, CYP3A5 and the MDR1 polymorphisms and gender on the urinary excretion of the metabolites of the H-receptor antihistamine ebastine: a pilot study. Br J Clin Pharmacol (2006) 0.81
Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups. Eur J Clin Pharmacol (2014) 0.78
Study of the Urinary Ratio of 6 beta-Hydroxycortisol/Cortisol as a Biomarker of CYP3A4 Activity in Egyptian Patients with Chronic Liver Diseases. Biomark Insights (2007) 0.77
Sex-dependent modulation of treatment response. Dialogues Clin Neurosci (2004) 0.77
Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum (1977) 8.55
Measurement of serum DNA-binding activity in systemic lupus erythematosus. N Engl J Med (1969) 6.16
Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med (1979) 5.58
Increased risk of lymphoma in sicca syndrome. Ann Intern Med (1978) 4.63
Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med (1986) 4.01
How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? Arthritis Rheum (1985) 2.68
Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med (1983) 2.38
Juvenile rheumatoid arthritis presenting in the adult as fever of unknown origin. Medicine (Baltimore) (1973) 2.21
Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals. Stroke (2001) 2.20
B-lymphocyte alloantigens associated with systemic lupus erythematosus. N Engl J Med (1978) 2.11
American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol (1999) 2.03
Incidence of infection in systemic lupus erythematosus. Arthritis Rheum (1974) 1.89
The medical cost of undiagnosed sleep apnea. Sleep (1999) 1.86
Differences in the clinical manifestations of sicca syndrome in the presence and absence of rheumatoid arthritis. Am J Med (1979) 1.79
Adverse drug events in elderly patients receiving home health services following hospital discharge. Ann Pharmacother (1999) 1.74
Cyclophosphamide in lupus nephritis: a controlled trial. Ann Intern Med (1971) 1.70
Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. J Clin Oncol (1998) 1.66
Bladder toxicity with chronic oral cyclophosphamide therapy in nonmalignant disease. Arthritis Rheum (1973) 1.61
NIH conference. Rheumatoid arthritis: evolving concepts of pathogenesis and treatment. Ann Intern Med (1984) 1.61
Primary amyloidosis. Clinical, immunochemical and immunoglobulin metabolism. Studies in fifteen patients. Am J Med (1969) 1.60
NIH conference. Systemic lupus erythematosus: evolving concepts. Ann Intern Med (1979) 1.59
Capillary tube migration for detection of human delayed hypersensitivity: difficulties encountered with "buffy coat" cells and tuberculin antigen. J Immunol (1969) 1.57
Inpatient costs, length of stay, and mortality for cerebrovascular events in community hospitals. Neurology (2001) 1.57
Clinical and economic impact of replacing divalproex sodium with valproic acid. Am J Health Syst Pharm (1997) 1.55
Mycoplasma hyorhinis swine arthritis. I. Clinical and microbiologic features. Arthritis Rheum (1971) 1.50
Presence of autoantibody for phospholipase inhibitory protein, lipomodulin, in patients with rheumatic diseases. Proc Natl Acad Sci U S A (1981) 1.47
Mycoplasma hyorhinis swine arthritis. II. Morphologic features. Arthritis Rheum (1971) 1.44
Lymphapheresis in rheumatoid arthritis. A randomized trial. Arthritis Rheum (1981) 1.41
Precipitous fall in platelet count with anagrelide: case report and critique of dosing recommendations. Pharmacotherapy (1997) 1.40
Complications of hysteroscopic treatments of menorrhagia. Br J Anaesth (1996) 1.38
The fourth component of complement in the cerebrospinal fluid in systemic Lupus erythematosus. Arthritis Rheum (1973) 1.37
Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall. Support Care Cancer (2003) 1.36
Medication adherence in elderly patients receiving home health services following hospital discharge. Ann Pharmacother (2001) 1.31
Abnormal structures in circulating lymphocytes from patients with systemic lupus erythematosus and related diseases. Arthritis Rheum (1973) 1.29
Influenza immunization in systemic lupus eruthematosus. A double-blind trial. Ann Intern Med (1978) 1.26
In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Pharmacol Ther (2000) 1.24
A solid-phase method for the quantitation of protein in the presence of sodium dodecyl sulfate and other interfering substances. Anal Biochem (1987) 1.23
Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther (1994) 1.23
Neutrophil chemotaxis in systemic lupus erythematosus. Ann Rheum Dis (1974) 1.22
Histocompatibility alloantigens in psoriasis and psoriatic arthritis. Evidence for the influence of multiple genes in the major histocompatibility complex. J Clin Invest (1980) 1.21
Reproducibility of multiple-observer scoring of radiologic abnormalities in the hands and wrists of patients with rheumatoid arthritis. Arthritis Rheum (1985) 1.20
A double-blind controlled trial comparing cyclophosphamide, azathioprine and placebo in the treatment of lupus glomerulonephritis. Arthritis Rheum (1975) 1.20
Pseudogout after parathyroidectomy. Lancet (1973) 1.19
Animal model distinguishing in vitro from in vivo carbenicillin-aminoglycoside interactions. Antimicrob Agents Chemother (1980) 1.19
Adult onset juvenile rheumatoid arthritis. Arthritis Rheum (1974) 1.13
Treating mammalian bite wounds. J Clin Pharm Ther (2000) 1.12
Effect of treatment on the evolution of renal abnormalities in lupus nephritis. N Engl J Med (1984) 1.11
Immune function in severe, active rheumatoid arthritis. A relationship between peripheral blood mononuclear cell proliferation to soluble antigens and synovial tissue immunohistologic characteristics. J Clin Invest (1984) 1.11
Detection of anti-interferon antibodies in systemic lupus erythematosus. Clin Exp Rheumatol (1985) 1.10
Lymphocyte depletion by continuous flow cell centrifugation in rheumatoid arthritis: clinical effects. Arthritis Rheum (1979) 1.10
Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet (2001) 1.10
A physiological approach to the assessment of disease activity in rheumatoid arthritis. J Clin Invest (1971) 1.10
Echocardiographic identification of cardiac abnormality in scleroderma and related disorders. Am J Med (1979) 1.09
Synthesis and biochemical studies of dithioate DNA. Ciba Found Symp (1991) 1.08
Reserpine in Raynaud's disease and phenomenon. Short-term response to intra-arterial injection. Ann Intern Med (1970) 1.08
Impaired delayed hypersensitivity in an aging population. Association with antinuclear reactivity and rheumatoid factor. JAMA (1968) 1.07
Biochemical and physicochemical properties of phosphorodithioate DNA. Biochemistry (1996) 1.06
Perception of chemotherapy side effects cancer versus noncancer patients. Cancer Pract (2000) 1.05
Multicenter evaluation of six methods for predicting warfarin maintenance-dose requirements from initial response. Clin Pharm (1985) 1.05
Marrow granulocyte reserves in the rheumatic diseases. Arthritis Rheum (1973) 1.04
Epstein-Barr virus antibody and lymphocyte tubuloreticular structures in systemic lupus erythematosus. Lancet (1973) 1.04
Leukapheresis in rheumatoid arthritis. Association of clinical improvement with reversal of anergy. Arthritis Rheum (1983) 1.03
Virologic studies on rheumatoid arthritis. Arthritis Rheum (1973) 1.03
Systemic lupus erythematosus. Contrasts and comparisons. Ann Intern Med (1975) 1.03
Central hyperventilation and inappropriate antidiuretic hormone secretion in systemic lupus erythemotosus. Am J Med (1970) 1.02
Effect of food on lidocaine kinetics: mechanism of food-related alteration in high intrinsic clearance drug elimination. Clin Pharmacol Ther (1981) 1.01
Human lymphocyte antigens characterizing psoriatic arthritis and its subtypes. J Rheumatol (1983) 0.99
Optimal management of amiodarone therapy: efficacy and side effects. Pharmacotherapy (1999) 0.99
Heart block in ankylosing spondylitis. Arch Intern Med (1966) 0.99
ARA presidential address. The final common pathway. Arthritis Rheum (1974) 0.99
Factors influencing serum protein binding of lidocaine in humans. Anesth Analg (1981) 0.99
Topically applied triamcinolone and macromolecular synthesis by human epidermis. J Invest Dermatol (1971) 0.98
In memoriam. Professor Anatoly I. Nesterov. Arthritis Rheum (1980) 0.97
Herpes zoster in patients with systemic lupus erythematosus. Arthritis Rheum (1978) 0.97
American Rheumatism Association nomenclature and classification of arthritis and rheumatism (1983). Arthritis Rheum (1983) 0.97
Septic arthritis due to Pasteurella multocida complicating rheumatoid arthritis. Arthritis Rheum (1968) 0.97
A cutaneous lesion associated with myositis. Ann Intern Med (1979) 0.96
Fever in systemic lupus erythematosus. Am J Med (1979) 0.96
Phase I study of a novel recombinant human soluble thrombomodulin, ART-123. J Thromb Haemost (2004) 0.96
Chloramphenicol sodium succinate kinetics in critically ill patients. Clin Pharmacol Ther (1980) 0.96
Hyperuricemia associated with uremia. Arthritis Rheum (1965) 0.96
Functional assessment of the rheumatoid hand. Am J Occup Ther (1969) 0.96
Hyperuricemia in Filipinos: interaction of heredity and environment. Am J Hum Genet (1967) 0.96
Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. Clin Pharmacol Ther (1998) 0.94
Bladder complications in patients receiving cyclophosphamide for systemic lupus erythematosus or rheumatoid arthritis. Ann Intern Med (1979) 0.94
Cyclophosphamide or azathioprine in lupus glomerulonephritis. A controlled trial: results at 28 months. Ann Intern Med (1975) 0.94
Error in anti-DNA antibody radioimmunoassay after gallium scanning. Ann Intern Med (1977) 0.93
Lymphocyte depletion and immunosuppression with repeated leukapheresis by continuous flow centrifugation. Blood (1981) 0.92
Mortality in lupus nephritis. Arthritis Rheum (1979) 0.92
Serum uric acid and obesity in Hawaiians. JAMA (1966) 0.91
Hepatic drug clearance in children: studies with indocyanine green as a model substrate. J Pharm Sci (1989) 0.91
Urinary fibrin split products in lupus nephritis. Correlation with other parameters of renal disease. Arthritis Rheum (1974) 0.91
Isolation of pyroGlu-Gly-Arg-Phe-NH2 (Antho-RFamide), a neuropeptide from sea anemones. Proc Natl Acad Sci U S A (1986) 0.90
A controlled study of pneumococcal polysaccharide vaccine in systemic lupus erythematosus. Arthritis Rheum (1979) 0.90
Methotrexate in rheumatoid arthritis. N Engl J Med (1985) 0.90
Comparative effects of aspirin and ibuprofen in the management of systemic lupus erythematosus. Arthritis Rheum (1980) 0.89
Gout in hospitalized Filipinos in Hawaii. Pac Med Surg (1967) 0.88
Altered protein binding of etoposide in patients with cancer. Clin Pharmacol Ther (1989) 0.88
Relative macrocytosis in cyclophosphamide and azathioprine therapy. JAMA (1974) 0.87
A multicenter evaluation of variables affecting the predictability of creatinine clearance. Am J Clin Pathol (1982) 0.87